Some studies have also clarified the new epigenetic mechanism of SLC16A3 promoter DNA methylation and/or MCT4 protein levels in thyroid cancer and clear cell renal cell carcinoma, which can provide a biological basis for clinical prognosis 68, 75, 76. Here, SLC16A3 is linked to thyroid cancer.